Immunotherapy combo shows promise against rare, tough ovarian cancer
NCT ID NCT03355976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of two immune-boosting drugs (nivolumab and ipilimumab) works better than nivolumab alone for people with advanced clear cell cancers of the ovary, fallopian tube, peritoneum, or other areas. About 46 participants will receive one of the two treatments to see if their tumors shrink. The goal is to find a new way to control these hard-to-treat cancers.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
University of Illinois Chicago
Chicago, Illinois, 60612, United States
-
Women & Infants Hospital
Providence, Rhode Island, 02905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can heated chemotherapy improve ovarian cancer outcomes?
- Can a new PET tracer light up hidden cancers?
- A Two-for-One surgery: could tube removal during Weight-Loss surgery slash ovarian cancer risk?
- Can AI spot ovarian cancer on CT scans before It's too late?
- Can Lab-Grown tumors unlock the secrets of ovarian cancer resistance?